{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"63.7","value":"228.0"}]}],"title":"Cycle 2 (n=335)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"71.5","value":"275.0"}]}],"title":"Cycle 6 (n=238)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"90.6","value":"299.0"}]}],"title":"Cycle 8 (n=36)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"335"}],"units":"Participants"}],"description":"Serum samples for rituximab pharmacokinetic analysis were taken pre-dose (within 15 minutes before rituximab infusion) and post-dose (within 15 minutes after the end of the rituximab infusion) after the first faster infusion (Cycle 2) and after the last infusion (either Cycle 6 or 8). An enzyme-linked immunosorbent assay (ELISA) was used to measure rituximab levels in the serum samples.","dispersionType":"Standard Deviation","groups":[{"description":"Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin \\[doxorubicin\\], Oncovin \\[vincristine\\], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m\\^2 administered by intravenous (IV) infusion on Day 1 of each cycle.","id":"OG000","title":"Rituximab 375 mg/m^2"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic evaluable population: All patients who received at least 1 infusion of rituximab and had rituximab concentration data.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycles 2 and either 6 or 8 (last cycle)","title":"Maximum Serum Concentration (Cmax) of Rituximab Post-dose at the First Alternative Dosing Rate (Cycle 2) and the Last Cycle (Either Cycle 6 or 8)","type":"SECONDARY","unitOfMeasure":"µg/mL"}